Loading
A phase 1 trial of Ilixadencel run by Mendus, completed.
Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT01974661 by Mendus, with 18 participants enrolled, started 2013-10. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: COMBIG-DC (ilixadencel).
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/